Rollover Extension Clinical Trial To Evaluate The Long-Term Safety And Efficacy Of US-APR2020 In Subjects With CKD IV Completing The US-APR2020-01 Study

• Status: Recruiting
• Trial end date: 2023-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an Open-Label Rollover Extension Clinical Trial to Evaluate the Long-Term Safety and Efficacy of US-APR2020 in Subjects With CKD IV Who Completed the US-APR2020-01 Study

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kibow Pharma

Criteria

Inclusion Criteria:

• Completion of US-APR2020-01 study

• Adults between the ages of 18-80 years

Exclusion Criteria:

• Did not participate in the placebo-controlled study US-APR2020-01

• Withdrew from US-APR2020-01 study prior to completing the 6 months treatment for any reason

• Unwilling or unable to visit the site for the follow-up visits